Eli Lilly presented indirect treatment comparisons showing its medicines Zepbound and Foundayo produced stronger results than Novo Nordisk semaglutide treatments in separate analyses. Lilly said Zepbound 15 mg generated about 5% more average weight loss than Wegovy HD over 72 weeks, while its previously reported analysis put the difference at 4.5%; the 10 mg dose was associated with roughly 3% additional weight loss, versus an earlier reported 3.2%. The company said patients on Zepbound 15 mg were about three times as likely to lose at least 20% of body weight, compared with an earlier estimate of four times higher odds, and discontinuations due to adverse events were comparable. In adults with type 2 diabetes, Lilly said Foundayo 17.2 mg delivered up to 2% greater weight loss and slightly better glycemic control than Novo's 25 mg oral semaglutide tablet. Earlier Lilly analyses reported a 1.5% weight-loss advantage and a 0.3 percentage-point greater A1C reduction, with alternative methods finding up to 2.4% and 0.6 percentage points, respectively. Novo Nordisk said the Foundayo analysis concerned diabetes patients rather than people treated solely for obesity, a distinction it said matters because weight loss is generally lower among diabetes patients. The 25 mg oral semaglutide dose is not approved in the United States for type 2 diabetes, and the FDA is expected to decide by late 2026.